Eagle Asset Management Inc. cut its holdings in Teladoc Health Inc (NYSE:TDOC) by 0.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 1,016,427 shares of the health services provider’s stock after selling 1,151 shares during the period. Eagle Asset Management Inc.’s holdings in Teladoc Health were worth $56,513,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Bank of New York Mellon Corp boosted its position in shares of Teladoc Health by 11.8% during the third quarter. Bank of New York Mellon Corp now owns 525,875 shares of the health services provider’s stock valued at $45,410,000 after buying an additional 55,522 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Teladoc Health during the third quarter valued at $9,145,000. Legal & General Group Plc boosted its position in shares of Teladoc Health by 13.5% during the third quarter. Legal & General Group Plc now owns 24,669 shares of the health services provider’s stock valued at $2,131,000 after buying an additional 2,943 shares during the last quarter. Federated Investors Inc. PA purchased a new stake in shares of Teladoc Health during the third quarter valued at $3,021,000. Finally, Vanguard Group Inc boosted its position in shares of Teladoc Health by 26.9% during the third quarter. Vanguard Group Inc now owns 5,874,182 shares of the health services provider’s stock valued at $507,236,000 after buying an additional 1,244,388 shares during the last quarter.
Shares of NYSE:TDOC opened at $62.55 on Tuesday. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of -43.44 and a beta of 1.38. The company has a debt-to-equity ratio of 0.42, a quick ratio of 8.53 and a current ratio of 7.54. Teladoc Health Inc has a 52-week low of $42.05 and a 52-week high of $89.05.
Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, February 27th. The health services provider reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). The business had revenue of $122.74 million for the quarter, compared to analysts’ expectations of $120.19 million. Teladoc Health had a negative return on equity of 10.86% and a negative net margin of 22.63%. As a group, equities analysts anticipate that Teladoc Health Inc will post -1.53 EPS for the current year.
In other news, insider Adam C. Vandervoort sold 5,550 shares of the firm’s stock in a transaction dated Friday, February 8th. The stock was sold at an average price of $61.69, for a total value of $342,379.50. Following the transaction, the insider now owns 2,934 shares of the company’s stock, valued at $180,998.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jason N. Gorevic sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $53.04, for a total value of $1,591,200.00. Following the completion of the transaction, the chief executive officer now directly owns 673,924 shares in the company, valued at approximately $35,744,928.96. The disclosure for this sale can be found here. Insiders sold 185,840 shares of company stock worth $11,242,619 over the last three months. Insiders own 3.95% of the company’s stock.
Several equities research analysts recently commented on TDOC shares. Zacks Investment Research raised Teladoc Health from a “sell” rating to a “hold” rating in a research report on Saturday, January 26th. Robert W. Baird raised Teladoc Health from a “neutral” rating to an “outperform” rating and set a $80.00 price objective on the stock in a research report on Monday, January 14th. They noted that the move was a valuation call. TheStreet raised Teladoc Health from a “d+” rating to a “c” rating in a research report on Wednesday, February 20th. Berenberg Bank started coverage on Teladoc Health in a research report on Thursday, January 31st. They set a “buy” rating and a $80.00 price objective on the stock. Finally, Craig Hallum reaffirmed a “buy” rating and set a $70.00 price objective (down from $80.00) on shares of Teladoc Health in a research report on Wednesday, May 1st. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $81.00.
COPYRIGHT VIOLATION WARNING: This report was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.thelincolnianonline.com/2019/05/07/eagle-asset-management-inc-has-56-51-million-holdings-in-teladoc-health-inc-tdoc.html.
Teladoc Health Profile
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Featured Article: What does RSI mean?
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.